184 related articles for article (PubMed ID: 34198999)
1. Radioimmunotheranostic Pair Based on the Anti-HER2 Monoclonal Antibody: Influence of Chelating Agents and Radionuclides on Biological Properties.
Miranda ACC; Dos Santos SN; Fuscaldi LL; Balieiro LM; Bellini MH; Guimarães MICC; de Araújo EB
Pharmaceutics; 2021 Jun; 13(7):. PubMed ID: 34198999
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 monoclonal antibody based-radioimmunoconjugates: Assessment of the chelating agent influence.
Miranda ACC; Durante ACR; Fuscaldi LL; Barbezan AB; de Lima CR; Perini E; de Araújo EB
Bioorg Med Chem; 2021 Mar; 33():115996. PubMed ID: 33494011
[TBL] [Abstract][Full Text] [Related]
3. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
4. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
5. [
Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
[TBL] [Abstract][Full Text] [Related]
6. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate.
MacPherson DS; Hwang D; Sarrett SM; Keinänen O; Rodriguez C; Rader C; Zeglis BM
Mol Pharm; 2023 Jan; 20(1):775-782. PubMed ID: 36377696
[TBL] [Abstract][Full Text] [Related]
7. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
8. Formulation and clinical translation of [
Guleria M; Sharma R; Amirdhanayagam J; Sarma HD; Rangarajan V; Dash A; Das T
RSC Med Chem; 2021 Mar; 12(2):263-277. PubMed ID: 34046615
[TBL] [Abstract][Full Text] [Related]
9. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
10. Comparative
Sharma R; Kameswaran M; Dash A
Cancer Biother Radiopharm; 2020 Apr; 35(3):177-189. PubMed ID: 32196365
[No Abstract] [Full Text] [Related]
11. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
13. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates.
Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA
Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142
[TBL] [Abstract][Full Text] [Related]
14. Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS; Parghane RV; Sahu S; Lad S; Deep K; Wanage G; Suralkar T; Banerjee S; Gupta S; Basu S; Badwe RA
Clin Nucl Med; 2024 Apr; 49(4):e149-e155. PubMed ID: 38350067
[TBL] [Abstract][Full Text] [Related]
15. Intricacies in the Preparation of Patient Doses of [
Chakraborty A; Mitra A; Sahu S; Tawate M; Lad S; Kamaldeep ; Rakshit S; Upadhye Bannore T; Gaikwad S; Dhotre G; Ray MK; Damle A; Basu S; Banerjee S
Mol Imaging Biol; 2024 Feb; 26(1):61-80. PubMed ID: 37673943
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Trifunctional Chelating Agents That Enhance Tumor Retention of Radioimmunoconjugates.
Nakashima K; Watanabe H; Ono M
J Med Chem; 2023 Sep; 66(18):12812-12827. PubMed ID: 37721492
[TBL] [Abstract][Full Text] [Related]
18. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
19. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
